Prot #MRG106-11-101: A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Su

Project: Research project

Project Details

StatusFinished
Effective start/end date12/8/156/30/19

Funding

  • Novella Clinical, LLC (Prot #MRG106-11-101)
  • miRagen Therapeutics, Inc. (Prot #MRG106-11-101)